share_log

Independent Non-Executive Director Ting Yuk Wu Sold A Bunch Of Shares In China Resources Medical Holdings

Independent Non-Executive Director Ting Yuk Wu Sold A Bunch Of Shares In China Resources Medical Holdings

独立非执行董事吴廷玉出售了华润医疗控股的大量股份
Simply Wall St ·  05/21 19:24

Anyone interested in China Resources Medical Holdings Company Limited (HKG:1515) should probably be aware that the Independent Non-Executive Director, Ting Yuk Wu, recently divested HK$2.6m worth of shares in the company, at an average price of HK$4.41 each. Equally important, that sale actually reduced their holding by a full 100% which hardly makes us feel bullish about the stock.

任何对华润医疗控股有限公司(HKG: 1515)感兴趣的人都应该知道,独立非执行董事吴丁玉最近以平均每股4.41港元的价格剥离了该公司价值260万港元的股份。同样重要的是,那次出售实际上使他们的持股量减少了整整100%,这几乎使我们对该股感到看涨。

China Resources Medical Holdings Insider Transactions Over The Last Year

华润医疗控股去年的内幕交易

Notably, that recent sale by Ting Yuk Wu is the biggest insider sale of China Resources Medical Holdings shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of HK$4.27. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

值得注意的是,Ting Yuk Wu最近的出售是我们去年对华润医疗控股股票的最大一次内幕出售。因此,我们知道一位内部人士以目前的4.27港元左右的股价出售了股票。尽管内幕抛售是负面的,但对我们来说,如果以较低的价格出售股票,则负面影响更大。鉴于此次出售是以当前价格进行的,这使我们有点谨慎,但并不是一个主要问题。

Ting Yuk Wu sold a total of 1.00m shares over the year at an average price of CN¥4.38. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

吴丁玉全年共出售了100万股股票,平均价格为4.38元人民币。您可以看到下图所示的去年的内幕交易(公司和个人)。如果你点击图表,你可以看到所有的个人交易,包括股价、个人和日期!

insider-trading-volume
SEHK:1515 Insider Trading Volume May 21st 2024
SEHK: 1515 内幕交易量 2024 年 5 月 21 日

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

如果你像我一样,那么你一定不想错过这份免费的小盘股清单,这些股票不仅被内部人士买入,而且估值也很有吸引力。

Insider Ownership Of China Resources Medical Holdings

华润医疗控股的内部所有权

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From looking at our data, insiders own HK$9.6m worth of China Resources Medical Holdings stock, about 0.2% of the company. But they may have an indirect interest through a corporate structure that we haven't picked up on. We prefer to see high levels of insider ownership.

对于普通股股东来说,值得检查一下公司内部人士持有多少股票。较高的内部所有权通常会使公司领导层更加关注股东的利益。从我们的数据来看,内部人士拥有价值960万港元的华润医疗控股股票,约占该公司0.2%的股份。但是,他们可能会通过我们尚未掌握的公司结构获得间接利益。我们更愿意看到高水平的内部所有权。

What Might The Insider Transactions At China Resources Medical Holdings Tell Us?

华润医疗控股的内幕交易可能告诉我们什么?

An insider sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we're not rushing to buy, to say the least. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing China Resources Medical Holdings. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of China Resources Medical Holdings.

一位内部人士最近出售了股票,但他们一直没有买入。在过去的一年里,没有任何能让我们感到安慰的购买。内部人士拥有该公司的股票相对较少,当你考虑销售情况时,我们对这只股票并不特别兴奋。因此,至少可以说,我们并不急于购买。除了了解正在进行的内幕交易外,确定华润医疗控股面临的风险也是有益的。为了帮助解决这个问题,我们发现了一个警告信号,你应该仔细看看,以更好地了解华润医疗控股的情况。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想看看另一家公司——一家财务状况可能优越的公司——那么千万不要错过这份免费的股本回报率高、债务低的有趣公司的名单。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发